Axsome Therapeutics Inc (19X.SG)
| Previous Close | 61.66 |
| Open | 60.66 |
| Bid | 63.52 x 200000 |
| Ask | 63.82 x 200000 |
| Day's Range | 60.66 - 63.52 |
| 52 Week Range | 52.38 - 92.00 |
| Volume | |
| Avg. Volume | 137 |
| Market Cap | 1.503B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | May 06, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireAxsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting
AXS-05 in Alzheimer’s disease agitation data featured in oral plenary session New data for AXS-07 in migraine demonstrating efficacy in pooled analysis Presentations on cognitive and wake promoting effects of solriamfetol NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced presentations highlighting its innovative p
- GlobeNewswire
Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6
NEW YORK, April 10, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced it will report its financial results for the first quarter of 2024 on Monday, May 6, 2024, before the opening of the U.S. financial markets. Axsome’s management team will host a conference call at 8:00 a.m. Eastern Time on May 6, 2024, to discuss these results and
ZacksAxsome (AXSM) Begins Solriamfetol Binge Eating Phase III Study
Axsome's (AXSM) phase III ENGAGE study is set to evaluate the efficacy and safety of solriamfetol for the treatment of binge eating disorder in adults.
